<p>Shown is the reactivity of sera from mice immunized with mixed L2 PP7 VLPs to L2 peptides. Mice were immunized i.m. three times with 10 µg of wild-type PP7 VLPs or 10 µg of mixed L2 PP7 VLPs. Sera were collected 2 weeks after the last immunization and serum anti-L2 IgG titer was determined by end-point dilution ELISA against streptavidin-conjugated HPV L2 peptides (amino acid 14–40) from HPV1, HPV5, HPV6, HPV16, and HPV18. Black-filled circles denote mice immunized with PP7 VLPs and diamonds denote mice immunized with mixed L2 PP7 VLPs.</p
<p>The anti-HPV16 L1 IgG and anti-HPV16 neutralizing antibody titers of the PBS-, hHPV16 VLP- and cH...
<p>Mice (n = 16 per group) were immunized three times with phosphate saline buffer (saline), with th...
<p>Groups of 5 Balb/c mice were immunized i.m. three times with 10 µg of PP7 VLPs or mixed L2 PP7 VL...
<p>(A) Groups of Balb/c mice were immunized twice intramuscularly at two-weeks interval with 5 µg ea...
<p>Two weeks after the third immunization with GST-HPV16L1Δ, GST-HPV16L1Δ-L2x3 or Cervarix®, two-fol...
<p>ELISA plates were coated with 500 ng of streptavidin-conjugated 16L2 peptides (amino acids 17–24,...
<p>Groups of mice were immunized twice with 10mer selectant VLPs or wild-type MS2 VLPs. Serum was ta...
<p>(A) Regimen of prime and boost vaccination was followed by viral challenge. IM0, IM1, and IM2 rep...
<p>C57BL/6 mice (5 per group) vaccinated twice intramuscularly with AAVLP(HPV16/31L2) particles eith...
<p><b>A</b>. Three groups of 16 BALB/c mice were immunized twice intraperitonealy with 10 µg of VLP-...
<p>Mice were immunized with low dose of AAVLP(HPV16/31L2) particles either twice (LD+M 2x) or three ...
Background: Current vaccines against HPVs are constituted of L1 protein self-assembled into virus-li...
<p>A. Sera of Balb/c mice immunized three times with 11–88×8 or 11–88×8Δ using Alum+MPL as adjuvant ...
E. coli-derived concatenated, multitype L2-conserved epitopes of human papillomavirus (HPV) L2 prote...
Background: Virus-like Particles (VLPs) display can be used to increase the immunogenicity of hetero...
<p>The anti-HPV16 L1 IgG and anti-HPV16 neutralizing antibody titers of the PBS-, hHPV16 VLP- and cH...
<p>Mice (n = 16 per group) were immunized three times with phosphate saline buffer (saline), with th...
<p>Groups of 5 Balb/c mice were immunized i.m. three times with 10 µg of PP7 VLPs or mixed L2 PP7 VL...
<p>(A) Groups of Balb/c mice were immunized twice intramuscularly at two-weeks interval with 5 µg ea...
<p>Two weeks after the third immunization with GST-HPV16L1Δ, GST-HPV16L1Δ-L2x3 or Cervarix®, two-fol...
<p>ELISA plates were coated with 500 ng of streptavidin-conjugated 16L2 peptides (amino acids 17–24,...
<p>Groups of mice were immunized twice with 10mer selectant VLPs or wild-type MS2 VLPs. Serum was ta...
<p>(A) Regimen of prime and boost vaccination was followed by viral challenge. IM0, IM1, and IM2 rep...
<p>C57BL/6 mice (5 per group) vaccinated twice intramuscularly with AAVLP(HPV16/31L2) particles eith...
<p><b>A</b>. Three groups of 16 BALB/c mice were immunized twice intraperitonealy with 10 µg of VLP-...
<p>Mice were immunized with low dose of AAVLP(HPV16/31L2) particles either twice (LD+M 2x) or three ...
Background: Current vaccines against HPVs are constituted of L1 protein self-assembled into virus-li...
<p>A. Sera of Balb/c mice immunized three times with 11–88×8 or 11–88×8Δ using Alum+MPL as adjuvant ...
E. coli-derived concatenated, multitype L2-conserved epitopes of human papillomavirus (HPV) L2 prote...
Background: Virus-like Particles (VLPs) display can be used to increase the immunogenicity of hetero...
<p>The anti-HPV16 L1 IgG and anti-HPV16 neutralizing antibody titers of the PBS-, hHPV16 VLP- and cH...
<p>Mice (n = 16 per group) were immunized three times with phosphate saline buffer (saline), with th...
<p>Groups of 5 Balb/c mice were immunized i.m. three times with 10 µg of PP7 VLPs or mixed L2 PP7 VL...